RxDoctor Payments DataLook up a doctor →

Frank Morocco, DO

Dermatology · Marion, OHNPI 1659508018

Payments from drug & device makers

$201,617in general payments, 2019–2025

Across 1,093 payments — averaging $184.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$54K
  • Amgen$42K
  • Galderma Laboratories, L.p.$33K
  • AbbVie$28K
  • Novartis$16K
  • Sanofi$7K
  • plus $22K from 30 others

What the payments were for

  • Consulting fees$28,75614%
  • Speaking & faculty fees$143,40671%
  • Travel & lodging$7,9134%
  • Food & beverage$20,93210%
  • Education$6100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$201,617 in reported general payments places this provider in the 90th percentile of 460 dermatology providers in Ohio.

See all dermatology providers in Ohio

Medicare billing

Part B allowed, 2024
$342,139
Medicare patients
1,146
Services billed
5,823

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab231$893,589
Skyrizi PenRisankizumab-Rzaa32$662,854
OtezlaApremilast99$498,800
Humira(Cf) PenAdalimumab26$468,781
Cosentyx Sensoready (2 Pens)Secukinumab50$382,489
Taltz AutoinjectorIxekizumab43$310,033
SkyriziRisankizumab-Rzaa13$267,427
TremfyaGuselkumab14$194,009
RinvoqUpadacitinib13$80,319
AdbryTralokinumab-Ldrm20$77,327
VtamaTapinarof40$55,453
Dupixent SyringeDupilumab14$51,754
ZoryveRoflumilast38$33,694
OpzeluraRuxolitinib Phosphate15$30,543
Clobetasol Propionate183$7,301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$41,729$498,80099 claims
AbbVieSkyrizi, Rinvoq$28,463$347,74626 claims
Johnson & JohnsonTremfya$5,283$194,00914 claims
LEO Pharma Inc.Adbry$266$77,32720 claims
Dermavant Sciences, Inc.Vtama$1,385$55,45340 claims
Arcutis Biotherapeutics, Inc.Zoryve$519$33,69438 claims
Incyte CorporationOpzelura$4,478$30,54315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 460 dermatology providers in Ohio.

Other dermatology in Marion

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →